220 results on '"Quinquenel A"'
Search Results
2. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
- Author
-
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, Luc-Mathieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drénou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Anne Quinquenel, Julien Broseus, Valérie Rouille, David Schwartz, Benoit Magnin, Grégory Lazarian, Lauren Véronèse, Marie de Antonio, Camille Laurent, Olivier Tournilhac, Bruno Pereira, and Pierre Feugier more...
- Subjects
Science - Abstract
Abstract Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle of R-CHOP, 25 of whom received blinatumomab. After blinatumomab induction, five (20%) patients achieved CR, four (16%) achieved partial response, and six (24%) were stable. Considering the entire strategy, the overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. The most common treatment-emergent adverse events of all grades in the blinatumomab-safety-set included fever (36%), anaemia (24%), and lymphopaenia (24%). Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT. more...
- Published
- 2024
- Full Text
- View/download PDF
Catalog
3. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
- Author
-
Dartigeas, Caroline, Quinquenel, Anne, Ysebaert, Loïc, Dilhuydy, Marie-Sarah, Anglaret, Bruno, Slama, Borhane, Le Du, Katell, Tardy, Stéphanie, Tchernonog, Emmanuelle, Orfeuvre, Hubert, Voillat, Laurent, Guidez, Stéphanie, Malfuson, Jean-Valère, Dupuis, Sandrine, Deslandes, Marine, Feugier, Pierre, and Leblond, Véronique more...
- Published
- 2024
- Full Text
- View/download PDF
4. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
- Author
-
Broséus, Julien, Hergalant, Sébastien, Vogt, Julia, Tausch, Eugen, Kreuz, Markus, Mottok, Anja, Schneider, Christof, Dartigeas, Caroline, Roos-Weil, Damien, Quinquenel, Anne, Moulin, Charline, Ott, German, Blanchet, Odile, Tomowiak, Cécile, Lazarian, Grégory, Rouyer, Pierre, Chteinberg, Emil, Bernhart, Stephan H., Tournilhac, Olivier, Gauchotte, Guillaume, Lomazzi, Sandra, Chapiro, Elise, Nguyen-Khac, Florence, Chery, Céline, Davi, Frédéric, Hunault, Mathilde, Houlgatte, Rémi, Rosenwald, Andreas, Delmer, Alain, Meyre, David, Béné, Marie-Christine, Thieblemont, Catherine, Lichter, Peter, Ammerpohl, Ole, Guéant, Jean-Louis, Guièze, Romain, Martin-Subero, José Ignacio, Cymbalista, Florence, Feugier, Pierre, Siebert, Reiner, and Stilgenbauer, Stephan more...
- Published
- 2023
- Full Text
- View/download PDF
5. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
- Author
-
Julien Broséus, Sébastien Hergalant, Julia Vogt, Eugen Tausch, Markus Kreuz, Anja Mottok, Christof Schneider, Caroline Dartigeas, Damien Roos-Weil, Anne Quinquenel, Charline Moulin, German Ott, Odile Blanchet, Cécile Tomowiak, Grégory Lazarian, Pierre Rouyer, Emil Chteinberg, Stephan H. Bernhart, Olivier Tournilhac, Guillaume Gauchotte, Sandra Lomazzi, Elise Chapiro, Florence Nguyen-Khac, Céline Chery, Frédéric Davi, Mathilde Hunault, Rémi Houlgatte, Andreas Rosenwald, Alain Delmer, David Meyre, Marie-Christine Béné, Catherine Thieblemont, Peter Lichter, Ole Ammerpohl, Jean-Louis Guéant, ICGC MMML-Seq Consortium, Romain Guièze, José Ignacio Martin-Subero, Florence Cymbalista, Pierre Feugier, Reiner Siebert, and Stephan Stilgenbauer more...
- Subjects
Science - Abstract
Richter syndrome (RS) is the transformation of chronic lymphocytic leukaemia (CLL) into aggressive lymphoma, in most cases diffuse large B-cell lymphoma (DLBCL). Here, the authors characterize the DNA methylation and transcriptomic profiles of RS samples, find a clonally-related CLL epigenetic imprint, and develop classifiers for “RS-type” de novo DLBCLs. more...
- Published
- 2023
- Full Text
- View/download PDF
6. PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
- Author
-
Anne Quinquenel, Marie Sarah Dilhuydy, Loïc Ysebaert, Stephane Lepretre, Christine Boileau, Gaëlle Cordonnier, Hassiba Ould Lahsen, and Vincent Levy
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
7. Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report
- Author
-
Hilal Hafian, Hubert Schvartz, Martine Patey, and Anne Quinquenel
- Subjects
Mucosa-associated lymphoid tissue (MALT) ,Monoclonal gammopathy ,Lymphoma ,Oral mucosa ,Light chain ,Haemopathy ,Dentistry ,RK1-715 - Abstract
Abstract Background Monoclonal gammopathy is a biological reality encountered in approximately 1% of the general population. In the absence of clinical and biological signs, it is considered of undetermined significance; however, it can be a biological signature of a monoclonal lymphocytic or plasma-cell proliferation. Their localisation to the oral mucosa remains rare and difficult to diagnose, particularly in indolent forms that escape imaging techniques. Case presentation Here, we report the case of a 73-year-old woman with a history of IgM kappa gammopathy followed for 13 years. The patient did not have a chronic infection or an autoimmune disease, and all the biological investigations and radiological explorations were unremarkable during this period. The discovery of a submucosal nodule in the cheek led to the diagnosis of MALT lymphoma and regression of half of the IgM kappa level after resection. The review of the literature shows the dominance of clinical signs (i.e., a mass or swelling) in the diagnosis of primary MALT lymphomas of the oral cavity after surgical resection. Conclusions Our case illustrates the role of examination of the oral cavity in the context of a monoclonal gammopathy. The absence of clinical and radiological evidence in favor of lymphoplasmacytic proliferation, does not exclude a primary indolent MALT lymphoma of the oral mucosa. more...
- Published
- 2021
- Full Text
- View/download PDF
8. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
- Author
-
Kevin Marquant, Anne Quinquenel, Carl Arndt, and Alexandre Denoyer
- Subjects
Multiple myeloma ,Antibody–drug conjugate ,Ocular toxicity ,Microcystic keratopathy ,In vivo confocal microscopy ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular surface inflammation, severe dry eye, and a specific toxicity to the cornea, namely microcystic keratopathy. While belamaf-induced ocular changes have not been prospectively studied, a better understanding of mechanisms involved as well as kinetics may aid in anticipating dose adjustment rather than stopping the treatment once clinical ocular damage is too severe. Case presentation A 61-year-old woman scheduled for belamaf as a fifth-line treatment against multiple myeloma was prospectively included. Clinical examinations were performed before and every 3 weeks afterward, together with in vivo confocal microscopy (IVCM) of the cornea. Visual acuity, symptoms, slit-lamp examination, and ultrastructural changes of the cornea were recorded according to the received dose of belamaf. More precisely, kinetics, shape, density, and location of the toxic corneal lesions have been followed and analyzed using IVCM. Also, specific lesions at the sub-basal nerve plexus layer were detected and characterized for the first time. This advanced approach allowed a better understanding of the belamaf-induced toxicity, further balancing the dose to maintain good vision and eye health while continuing the treatment. Conclusions Systematic ultrastructural analysis and follow-up of the corneal state during ADCs treatment for multiple myeloma may open new avenues in the therapeutic approach. Early preclinical detection of ocular damage may accurately contribute to finding the correct dose for each patient and not stopping the treatment due to severe ocular adverse effects. more...
- Published
- 2021
- Full Text
- View/download PDF
9. Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
- Author
-
Carole Durot, Eric Durot, Sébastien Mulé, David Morland, François Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, and Christine Hoeffel
- Subjects
follicular lymphoma ,positron emission tomography ,tomography ,X-ray computed ,Medicine (General) ,R5-920 - Abstract
The purpose of this study was to determine whether texture analysis features present on pretreatment unenhanced computed tomography (CT) images, derived from 18F-fluorodeoxyglucose positron emission/computed tomography (18-FDG PET/CT), can predict progression-free survival (PFS), progression-free survival at 24 months (PFS 24), time to next treatment (TTNT), and overall survival in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Seventy-two patients with follicular lymphoma were retrospectively included. Texture analysis was performed on unenhanced CT images extracted from 18-FDG PET/CT examinations that were obtained within one month before treatment. Skewness at a fine texture scale (SSF = 2) was an independent predictor of PFS (hazard ratio = 3.72 (95% CI: 1.15, 12.11), p = 0.028), PFS 24 (hazard ratio = 13.38; 95% CI: 1.29, 138.13; p = 0.029), and TTNT (hazard ratio = 5.11; 95% CI: 1.18, 22.13; p = 0.029). Skewness values above −0.015 at SSF = 2 were significantly associated with lower PFS, PFS 24, and TTNT. Kurtosis without filtration was an independent predictor of PFS (SSF = 0; HR = 1.22 (95% CI: 1.04, 1.44), p = 0.013), and TTNT (SSF = 0; hazard ratio = 1.23; 95% CI: 1.04, 1.46; p = 0.013). This study shows that pretreatment unenhanced CT texture analysis-derived tumor skewness and kurtosis may be used as predictive biomarkers of PFS and TTNT in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. more...
- Published
- 2023
- Full Text
- View/download PDF
10. Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
- Author
-
Anne‐Cécile Gauchy, Maxime Hentzien, Alain Wynckel, Victoire de Marcellus, Cyrielle Rodier, Alain Delmer, and Anne Quinquenel
- Subjects
chronic myelomonocytic leukemia ,eculizumab ,warm autoimmune hemolytic anemia ,Medicine ,Medicine (General) ,R5-920 - Abstract
Abstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments. more...
- Published
- 2020
- Full Text
- View/download PDF
11. Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report
- Author
-
Hafian, Hilal, Schvartz, Hubert, Patey, Martine, and Quinquenel, Anne
- Published
- 2021
- Full Text
- View/download PDF
12. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
- Author
-
Marquant, Kevin, Quinquenel, Anne, Arndt, Carl, and Denoyer, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
13. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome
- Author
-
Hélène Augé, Anne-Béatrice Notarantonio, Romain Morizot, Anne Quinquenel, Luc-Matthieu Fornecker, Sébastien Hergalant, Pierre Feugier, and Julien Broséus
- Subjects
Richter syndrome ,chronic lymphocytic leukemia ,diffuse large B-cell lymphoma ,genomics ,microenvironment ,immune checkpoint ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionRichter Syndrome (RS) is defined as the development of an aggressive lymphoma in the context of Chronic Lymphocytic Leukemia (CLL), with a Diffuse Large B-Cell Lymphoma (DLBCL) histology in 95% cases. RS genomic landscape shares only a few features with de novo DLBCLs and is marked by a wide spectrum of cytogenetic abnormalities. Little is known about RS microenvironment. Therapeutic options and efficacy are limited, leading to a 12 months median overall survival. The new targeted treatments usually effective in CLL fail to obtain long-term remissions in RS.MethodsWe reviewed available PubMed literature about RS genomics, PD-1/PD-L1 (Programmed Death 1/Programmed Death Ligand 1) pathway triggering and subsequent new therapeutic options.ResultsData from about 207 patients from four landmark papers were compiled to build an overview of RS genomic lesions and point mutations. A number of these abnormalities may be involved in tumor microenvironment reshaping. T lymphocyte exhaustion through PD-L1 overexpression by tumor cells and subsequent PD-1/PD-L1 pathway triggering is frequently reported in solid cancers. This immune checkpoint inhibitor is also described in B lymphoid malignancies, particularly CLL: PD-1 expression is reported in a subset of prolymphocytes from the CLL lymph node proliferation centers. However, there is only few data about PD-1/PD-L1 pathway in RS. In RS, PD-1 expression is a hallmark of recently described « Regulatory B-cells », which interact with tumor microenvironment by producing inhibiting cytokines such as TGF-β and IL-10, impairing T lymphocytes anti-tumoral function. Based upon the discovery of high PD-1 expression on tumoral B lymphocyte from RS, immune checkpoint blockade therapies such as anti-PD-1 antibodies have been tested on small RS cohorts and provided heterogeneous but encouraging results.ConclusionRS genetic landscape and immune evasion mechanisms are being progressively unraveled. New protocols using targeted treatments such as checkpoint inhibitors as single agents or in combination with immunochemotherapy are currently being evaluated. more...
- Published
- 2020
- Full Text
- View/download PDF
14. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
- Author
-
Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, Florence Cymbalista, Caroline Dartigeas, Frédéric Davi, Sophie de Guibert, Alain Delmer, Marie-Sarah Dilhuydy, Pierre Feugier, Luc-Matthieu Fornecker, David Ghez, Romain Guieze, Kamel Laribi, Véronique Leblond, Stéphane Leprêtre, Rémi Letestu, Vincent Lévy, Florence Nguyen-Khac, Anne-Sophie Michallet, Cécile Tomowiak, Olivier Tournilhac, Loïc Ysebaert, Xavier Troussard, and on the behalf of the FILO-LLC Group more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract. As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome. more...
- Published
- 2020
- Full Text
- View/download PDF
15. PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
- Author
-
Quinquenel, Anne, primary, Dilhuydy, Marie Sarah, additional, Ysebaert, Loïc, additional, Lepretre, Stephane, additional, Boileau, Christine, additional, Cordonnier, Gaëlle, additional, Lahsen, Hassiba Ould, additional, and Levy, Vincent, additional more...
- Published
- 2023
- Full Text
- View/download PDF
16. Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
- Author
-
Durot, Carole, primary, Durot, Eric, additional, Mulé, Sébastien, additional, Morland, David, additional, Godard, François, additional, Quinquenel, Anne, additional, Delmer, Alain, additional, Soyer, Philippe, additional, and Hoeffel, Christine, additional more...
- Published
- 2023
- Full Text
- View/download PDF
17. Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
- Author
-
Hoeffel, Carole Durot, Eric Durot, Sébastien Mulé, David Morland, François Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, and Christine
- Subjects
follicular lymphoma ,positron emission tomography ,tomography ,X-ray computed - Abstract
The purpose of this study was to determine whether texture analysis features present on pretreatment unenhanced computed tomography (CT) images, derived from 18F-fluorodeoxyglucose positron emission/computed tomography (18-FDG PET/CT), can predict progression-free survival (PFS), progression-free survival at 24 months (PFS 24), time to next treatment (TTNT), and overall survival in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Seventy-two patients with follicular lymphoma were retrospectively included. Texture analysis was performed on unenhanced CT images extracted from 18-FDG PET/CT examinations that were obtained within one month before treatment. Skewness at a fine texture scale (SSF = 2) was an independent predictor of PFS (hazard ratio = 3.72 (95% CI: 1.15, 12.11), p = 0.028), PFS 24 (hazard ratio = 13.38; 95% CI: 1.29, 138.13; p = 0.029), and TTNT (hazard ratio = 5.11; 95% CI: 1.18, 22.13; p = 0.029). Skewness values above −0.015 at SSF = 2 were significantly associated with lower PFS, PFS 24, and TTNT. Kurtosis without filtration was an independent predictor of PFS (SSF = 0; HR = 1.22 (95% CI: 1.04, 1.44), p = 0.013), and TTNT (SSF = 0; hazard ratio = 1.23; 95% CI: 1.04, 1.46; p = 0.013). This study shows that pretreatment unenhanced CT texture analysis-derived tumor skewness and kurtosis may be used as predictive biomarkers of PFS and TTNT in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. more...
- Published
- 2023
- Full Text
- View/download PDF
18. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
- Author
-
Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, and Anne-Sophie Michallet more...
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
19. Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report
- Author
-
Martine Patey, Anne Quinquenel, Hubert Schvartz, and Hilal Hafian
- Subjects
Pathology ,medicine.medical_specialty ,Lymphoma ,Lymphoid Tissue ,Population ,Case Report ,Context (language use) ,Head and neck ,Gammopathy ,Mucosa-associated lymphoid tissue (MALT) ,medicine ,Humans ,Oral mucosa ,education ,General Dentistry ,Haemopathy ,Aged ,Autoimmune disease ,Mouth ,education.field_of_study ,Light chain ,business.industry ,Monoclonal gammopathy ,Mouth Mucosa ,MALT lymphoma ,RK1-715 ,Lymphoma, B-Cell, Marginal Zone ,medicine.disease ,medicine.anatomical_structure ,Dentistry ,Monoclonal ,Female ,Persistent Infection ,Extra nodal ,business - Abstract
Background Monoclonal gammopathy is a biological reality encountered in approximately 1% of the general population. In the absence of clinical and biological signs, it is considered of undetermined significance; however, it can be a biological signature of a monoclonal lymphocytic or plasma-cell proliferation. Their localisation to the oral mucosa remains rare and difficult to diagnose, particularly in indolent forms that escape imaging techniques. Case presentation Here, we report the case of a 73-year-old woman with a history of IgM kappa gammopathy followed for 13 years. The patient did not have a chronic infection or an autoimmune disease, and all the biological investigations and radiological explorations were unremarkable during this period. The discovery of a submucosal nodule in the cheek led to the diagnosis of MALT lymphoma and regression of half of the IgM kappa level after resection. The review of the literature shows the dominance of clinical signs (i.e., a mass or swelling) in the diagnosis of primary MALT lymphomas of the oral cavity after surgical resection. Conclusions Our case illustrates the role of examination of the oral cavity in the context of a monoclonal gammopathy. The absence of clinical and radiological evidence in favor of lymphoplasmacytic proliferation, does not exclude a primary indolent MALT lymphoma of the oral mucosa. more...
- Published
- 2021
20. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
- Author
-
Anne Quinquenel, Kevin Marquant, Carl Arndt, Alexandre Denoyer, Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de la Vision, Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre Hospitalier Universitaire de Reims (CHU Reims), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), and Gestionnaire, HAL Sorbonne Université 5 more...
- Subjects
In vivo confocal microscopy ,Cancer Research ,medicine.medical_specialty ,Antibody-drug conjugate ,Visual acuity ,genetic structures ,Case Report ,Antibodies, Monoclonal, Humanized ,Microcystic keratopathy ,Corneal Diseases ,Cornea ,03 medical and health sciences ,0302 clinical medicine ,Ocular toxicity ,Multiple myeloma ,Internal medicine ,Ophthalmology ,Humans ,Medicine ,Diseases of the blood and blood-forming organs ,[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs ,Adverse effect ,Molecular Biology ,RC254-282 ,Microscopy, Confocal ,Hematology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Middle Aged ,medicine.disease ,eye diseases ,3. Good health ,Discontinuation ,medicine.anatomical_structure ,Oncology ,[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs ,030220 oncology & carcinogenesis ,Toxicity ,030221 ophthalmology & optometry ,Female ,sense organs ,medicine.symptom ,RC633-647.5 ,business ,Antibody–drug conjugate - Abstract
Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular surface inflammation, severe dry eye, and a specific toxicity to the cornea, namely microcystic keratopathy. While belamaf-induced ocular changes have not been prospectively studied, a better understanding of mechanisms involved as well as kinetics may aid in anticipating dose adjustment rather than stopping the treatment once clinical ocular damage is too severe. Case presentation A 61-year-old woman scheduled for belamaf as a fifth-line treatment against multiple myeloma was prospectively included. Clinical examinations were performed before and every 3 weeks afterward, together with in vivo confocal microscopy (IVCM) of the cornea. Visual acuity, symptoms, slit-lamp examination, and ultrastructural changes of the cornea were recorded according to the received dose of belamaf. More precisely, kinetics, shape, density, and location of the toxic corneal lesions have been followed and analyzed using IVCM. Also, specific lesions at the sub-basal nerve plexus layer were detected and characterized for the first time. This advanced approach allowed a better understanding of the belamaf-induced toxicity, further balancing the dose to maintain good vision and eye health while continuing the treatment. Conclusions Systematic ultrastructural analysis and follow-up of the corneal state during ADCs treatment for multiple myeloma may open new avenues in the therapeutic approach. Early preclinical detection of ocular damage may accurately contribute to finding the correct dose for each patient and not stopping the treatment due to severe ocular adverse effects. more...
- Published
- 2021
- Full Text
- View/download PDF
21. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
- Author
-
Quinquenel, Anne, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Aurran-Schleinitz, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Véronique, additional, Dilhuydy, Marie-Sarah, additional, Dartigeas, Caroline, additional, Tomowiak, Cecile, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Lepretre, Stephane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen Khac, Florence, additional, Rouille, Valérie, additional, Delmer, Alain, additional, and Michallet, Anne-Sophie, additional more...
- Published
- 2022
- Full Text
- View/download PDF
22. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
- Author
-
Godet, Sophie, Protin, Caroline, Dupuis, Jehan, Dartigeas, Caroline, Bastie, Jean‐Noël, Herbaux, Charles, Leblond, Véronique, de Guibert, Sophie, Ghez, David, Brion, Annie, Ysebaert, Loïc, Delmer, Alain, and Quinquenel, Anne more...
- Published
- 2018
- Full Text
- View/download PDF
23. Myeloid malignancies with translocation t(4;12)(q11‐13;p13): molecular landscape, clonal hierarchy and clinical outcomes
- Author
-
François Lifermann, Jean-Alain Martignoles, Anne Quinquenel, Vincent Parinet, Christine Lefebvre, Pierre Hirsch, Mélanie Martin, Sabine Defasque, Florence Nguyen-Khac, Matthieu Decamp, Laurence Simon, Dominique Penther, Nadia Ali-Ammar, Elise Chapiro, Odile Maarek, Chrystele Bilhou-Nabera, Baptiste Gaillard, Agathe Maillon, Jean-Baptiste Micol, Marine Baron, Nathalie Auger, Stéphanie Struski, Damien Roos-Weil, Sylvie Tondeur, Marie-Joelle Mozziconacci, Audrey Bidet, Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Robert Debré, Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratoire CERBA [Saint Ouen l'Aumône], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Génétique [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier de Dax, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Génétique (Biologie pathologie), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Service d'immunologie et hématologies biologiques [CHU Saint-Antoine], Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), HAL-SU, Gestionnaire, École Pratique des Hautes Études (EPHE), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM) more...
- Subjects
Male ,Oncology ,Myeloid ,[SDV]Life Sciences [q-bio] ,Chromosomal translocation ,Translocation, Genetic ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,12) ,In Situ Hybridization, Fluorescence ,Aged, 80 and over ,CHIC2 ,Middle Aged ,Immunohistochemistry ,3. Good health ,[SDV] Life Sciences [q-bio] ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,RUNX1 ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Cohort ,Molecular Medicine ,Female ,Original Article ,Chromosomes, Human, Pair 4 ,medicine.medical_specialty ,IDH1 ,03 medical and health sciences ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,acute myeloid leukaemia ,Genetic Association Studies ,Aged ,Chromosome Aberrations ,Chromosomes, Human, Pair 12 ,Myeloproliferative Disorders ,business.industry ,Myelodysplastic syndromes ,Original Articles ,ETV6 ,Cell Biology ,medicine.disease ,myelodysplastic syndrome ,t(4 ,chemistry ,Fusion transcript ,Myelodysplastic Syndromes ,prognosis ,business ,030215 immunology - Abstract
International audience; Translocation t(4;12)(q11-13;p13) is a recurrent but very rare chromosomal aberration in acute myeloid leukaemia (AML) resulting in the non-constant expression of a CHIC2/ETV6 fusion transcript. We report clinico-biological features, molecular characteristics and outcomes of 21 cases of t(4;12) including 19 AML and two myelodysplastic syndromes (MDS). Median age at the time of t(4;12) was 78 years (range, 56–88). Multilineage dysplasia was described in 10 of 19 (53%) AML cases and CD7 and/or CD56 expression in 90%. FISH analyses identified ETV6 and CHIC2 region rearrangements in respectively 18 of 18 and 15 of 17 studied cases. The t(4;12) was the sole cytogenetic abnormality in 48% of cases. The most frequent associated mutated genes were ASXL1 (n = 8/16, 50%), IDH1/2 (n = 7/16, 44%), SRSF2 (n = 5/16, 31%) and RUNX1 (n = 4/16, 25%). Interestingly, concurrent FISH and molecular analyses showed that t(4;12) can be, but not always, a founding oncogenic event. Median OS was 7.8 months for the entire cohort. In the 16 of 21 patients (76%) who received antitumoral treatment, overall response and first complete remission rates were 37% and 31%, respectively. Median progression-free survival in responders was 13.7 months. Finally, t(4;12) cases harboured many characteristics of AML with myelodysplasia-related changes (multilineage dysplasia, MDS-related cytogenetic abnormalities, frequent ASXL1 mutations) and a poor prognosis. more...
- Published
- 2021
- Full Text
- View/download PDF
24. Corneal iatrogenicity of Belantamab Mafodotin (GSK2857916), Clinical and Morphological In Vivo Confocal Microscopy follow-up of a case series
- Author
-
David Mostrel, Kevin Marquant, Anne Quinquenel, Carl Arndt, and Alexandre Denoyer
- Abstract
Objective : To highlight the potential importance of confocal microscopy (IVCM) in the follow-up of patients with refractory multiple myeloma treated with Belantamab Mafodotin. Methods : A retrospective case series of 8 patients with refractory multiple myeloma treated with belantamab mafodotin was reported. Ophthalmologic follow-up of these patients every 3 weeks before each new infusion included systematic corneal examination with IVCM. A complementary analysis of the morphological data collected in IVCM was performed to evaluate the density, the average size and the circularity of the lesions observed. Results : In case 1, the iatrogenic damage was maximal at the 6th week of follow-up with an important damage of Bowman's layer, leading to the suspension of the treatment. After resumption of treatment at a reduced dosage, the morphological damage to the cornea was reduced. In case 2, the onset of iatrogenic damage related to the treatment was observed but the follow-up was interrupted early because of therapeutic escape of the disease. In case 3, a prolonged follow-up could be performed showing a good tolerance to the treatment. In case 4, a decrease in visual acuity was observed at the 6th week of follow-up in connection with the treatment-related toxicity well observed in IVCM. Follow-up was then interrupted due to therapeutic escape of the disease. In cases 5 and 6, a significant decrease in visual acuity was observed at the 6th week in relation to iatrogenic morphological anomalies of the central cornea. The resumption of treatment at a reduced dosage was accompanied by an improved tolerance. In cases 7 and 8, the patients did not develop specific damage. Conclusion : Our study showed the interest of corneal morphological follow-up in IVCM in patients treated with belantamab mafodotin in order to detect early signs of corneal iatrogenicity and to guide the management accordingly, before the suspension of treatment. more...
- Published
- 2022
- Full Text
- View/download PDF
25. Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
- Author
-
Quinquenel, Anne, Maestraggi, Quentin, Lecoq-Lafon, Carinne, Régis, Peffault de Latour, Delmer, Alain, and Servettaz, Amélie
- Published
- 2017
- Full Text
- View/download PDF
26. Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study
- Author
-
Lemoine, Amélie, primary, Perrier, Marine, additional, Mazza, Camille, additional, Quinquenel, Anne, additional, Brasseur, Mathilde, additional, Delmer, Alain, additional, Vallerand, Hervé, additional, Dewolf, Maxime, additional, Bertin, Eric, additional, Barbe, Coralie, additional, Botsen, Damien, additional, and Bouché, Olivier, additional more...
- Published
- 2022
- Full Text
- View/download PDF
27. Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study
- Author
-
Amélie Lemoine, Marine Perrier, Camille Mazza, Anne Quinquenel, Mathilde Brasseur, Alain Delmer, Hervé Vallerand, Maxime Dewolf, Eric Bertin, Coralie Barbe, Damien Botsen, and Olivier Bouché
- Subjects
Cancer Research ,Oncology ,adapted physical activity ,feasibility ,muscle strength ,anxiety ,cancer patients - Abstract
Adapted physical activity (APA) improves quality of life and cancer outcomes. The aim of this study was to assess the feasibility of an APA program in outpatients beginning medical anticancer treatment. The secondary objective was to assess the impact of APA on fatigue, anxiety, depression, and handgrip strength (HGS). This prospective study was conducted between January and July 2017. Among 226 patients beginning treatment in the unit for a digestive, lung, hematological, or dermatological cancer, 163 were included. Adherence to the APA program was defined as more than or equal to one one-hour session per week for 3 months. The first evaluation was conducted at 3 months (M3), and the second evaluation at 6 months (M6). A total of 163 patients were included (mean age 62.5 ± 14.3); 139 (85.3%) agreed to follow the APA program. At M3, 106 of them were evaluated, of which 86 (81.1%) declared that they had followed the program. Improvement in anxiety was observed at M3 (−1.0 ± 3.2; p = 0.002) but there was no significant change in fatigue or depression. HGS decreased significantly (−1.2 ± 5.5; p = 0.04). The APA program was feasible in cancer outpatients beginning medical anticancer treatment. APA should be part of standard support care. more...
- Published
- 2022
28. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
- Author
-
Lazarian, Grégory, Theves, Floriane, Hormi, Myriam, Letestu, Rémi, Eclache, Virginie, Bidet, Audrey, Cornillet-Lefebvre, Pascale, Davi, Frédéric, Delabesse, Eric, Estienne, Marie-Hélène, Etancelin, Pascaline, Kosmider, Olivier, Laibe, Sophy, Lode, Laurence, Muller, Marc, Nadal, Nathalie, Naguib, Dina, Pastoret, Cédric, Poulain, Stéphanie, Sujobert, Pierre, Veronese, Lauren, Imache, Samia, Lefebvre, Valérie, Cymbalista, Florence, Baran-Marszak, Fanny, Soussi, Thierry, Aurran, Thérese, Herbaux, Charles, Cartron, Guillaume, Dartigeas, Caroline, Delmer, Alain, Dupuis, Jehan, Dilhuydy, Marie, Ferrant, Emmanuelle, Feugier, Pierre, Genevieve, Franck, de Guibert, Sophie, Guieze, Romain, Leblond, Véronique, Levy, Vincent, Leprêtre, Stephane, Merabet, Fatiha, Michallet, Anne-Sophie, Nguyen-Khac, Florence, Quinquenel, Anne, Raynaud, Sophie, Re, Daniel, Thieblemont, Catherine, Tournillhac, Olivier, Troussard, Xavier, Truchan-Graczyk, Malgorzata, Willems, Lise, Ysebaert, Loic, Zini, Jean-Marc, Service d'hématologie biologique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord, Service d'Hématologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hématologie Biologique [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service d'hématologie [Reims], Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims)-Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hématologie biologique [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Département d'Oncologie Génétique [Rouen] (CLCC Henri Becquerel), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Laboratoire Bio-Santis, Cavaillon, France, Laboratoire d'oncobiologie [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Génétique Médicale (CHU de Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire de Génétique Chromosomique et Moléculaire [CHU Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'hématologie biologique [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Pontchaillou [Rennes], Service d'Hématologie Cellulaire [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hématologie Cellulaire [Hospices civils de Lyon], Hospices Civils de Lyon, Lyon, France, Hospices Civils de Lyon (HCL), Service de Cytogénétique Médicale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Mort cellulaire programmée et résistance aux drogues dans les hémopathies malignes = Cell death and Drug Resistance in Hematological Disorders [CRC], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Uppsala University, French Innovative Leukemia Organization (Filo), Cancéropole Ille de France. Grant Number: 2019-1-EMERG-22-INSERM 6-1, Service d'Hématologie Biologique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), and Gestionnaire, Hal Sorbonne Université more...
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Mutation ,Humans ,Chlorambucil ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Tumor Suppressor Protein p53 ,Codon ,Leukemia, Lymphocytic, Chronic, B-Cell ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2022
- Full Text
- View/download PDF
29. Th17/Treg ratio in human graft-versus-host disease
- Author
-
Ratajczak, Philippe, Janin, Anne, Peffault de Latour, Regis, Leboeuf, Christophe, Desveaux, Allison, Keyvanfar, Keyvan, Robin, Marie, Clave, Emmanuel, Douay, Corine, Quinquenel, Anne, Pichereau, Claire, Bertheau, Philippe, Mary, Jean Yves, and Socié, Gérard more...
- Published
- 2010
- Full Text
- View/download PDF
30. Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group
- Author
-
Doublet, Charlotte, primary, Dilhuydy, Marie-Sarah, additional, Ferrant, Emmanuelle, additional, Feugier, Pierre, additional, Fayault, Alexandra, additional, Robert, Philippine, additional, Lepretre, Stephane, additional, Delmer, Alain, additional, Tomowiak, Cécile, additional, Guieze, Romain, additional, Laribi, Kamel, additional, Vignon, Marguerite, additional, Clavert, Aline, additional, Bijou, Fontanet, additional, Re, Daniel, additional, Lara, Diane, additional, Merabet, Fatiha, additional, Tchernonog, Emmanuelle, additional, Dartigeas, Caroline, additional, Michallet, Anne-Sophie, additional, and Quinquenel, Anne, additional more...
- Published
- 2021
- Full Text
- View/download PDF
31. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
- Author
-
Michallet, Anne-Sophie, primary, Quinquenel, Anne, additional, Letestu, Remi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Elsensohn, Mad-Helenie, additional, Aurran, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Veronique, additional, Dilhuydy, Marie-Sarah, additional, Tomowiak, Cécile, additional, Dartigeas, Caroline, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Leprêtre, Stéphane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen-Khac, Florence, additional, Rouille, Valérie, additional, and Delmer, Alain, additional more...
- Published
- 2021
- Full Text
- View/download PDF
32. Impact of MYD88 L265P mutation status on histological transformation of Waldenström Macroglobulinemia
- Author
-
Gita Thanarajasingam, Anne Quinquenel, Anne J. Novak, Angela Dispenzieri, Nelson Leung, Wilson I. Gonsalves, Rebecca L. King, Prashant Kapoor, Rong He, Jose C. Villasboas, Ronald S. Go, Carrie A. Thompson, Yi Lin, Robert A. Kyle, Taxiarchis Kourelis, Thomas E. Witzig, Jennifer Le-Rademacher, Shaji Kumar, Gabriela Perez Burbano, S. Vincent Rajkumar, Jithma P. Abeykoon, Rahma Warsame, Eli Muchtar, Patrick B. Johnston, Francis K. Buadi, Patricia T. Greipp, Pascale Cornillet-Lefebvre, Ivana N. Micallef, Eric Durot, Alain Delmer, David J. Inwards, Thomas M. Habermann, Martha Q. Lacy, N. Nora Bennani, Saurabh Zanwar, David Dingli, Grzegorz S. Nowakowski, Morie A. Gertz, and Stephen M. Ansell more...
- Subjects
medicine.medical_specialty ,Multivariate analysis ,business.industry ,Waldenstrom macroglobulinemia ,Hematology ,Odds ratio ,medicine.disease ,Gastroenterology ,Lymphoma ,Internal medicine ,Cohort ,medicine ,Missense mutation ,business ,Complication ,Survival rate - Abstract
Histological transformation in Waldenstrom macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated with transformation in WM, highlighting the role of MYD88 L265P mutation. Patients with WM seen at Mayo Clinic, Rochester, USA and University Hospital of Reims, France, between 01/01/1996 and December 31, 2017 were included; 50 (4.3%) of 1147 patients transformed to a high-grade lymphoma, with median time-to-transformation of 4.5 (range 0-21) years in the transformed cohort. The MYD88 L265P mutation status was known in 435/1147 (38%) patients (406 with non-transformed WM and 29 patients in transformed cohort). On multivariate analysis, MYD88 WT status alone was an independent predictor of transformation (odds ratio, 7[95%CI: 2.1-23]; P = .003). Additionally, the MYD88 WT status was independently associated with shorter time-to-transformation (HR 7.9 [95%CI: 2.3-27; P = .001]), with a 5-year transformation rate of 16% for MYD88 WT vs 2.8% with MYD88 L265P mutated patients. Patients with transformation demonstrated a significant increase in risk of death compared to patients who did not transform (HR 5.075; 95%CI: 3.8-6.8; P < .001). In conclusion, the MYD88 WT status is an independent predictor of transformation and associated with a shorter time-to-transformation. Additionally, transformation conferred an inferior overall survival in patients with WM. more...
- Published
- 2019
- Full Text
- View/download PDF
33. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)
- Author
-
Quinquenel, Anne, Willekens, Christophe, Dupuis, Jehan, Royer, Bruno, Ysebaert, Loic, Guibert, De S., Michallet, Anne-Sophie, Feugier, Pierre, Guieze, Romain, Levy, Vincent, and Delmer, Alain
- Published
- 2015
- Full Text
- View/download PDF
34. Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
- Author
-
Quinquenel, Anne, Al Nawakil, Chadi, Baran-Marszak, Fanny, Eclache, Virginie, Letestu, Remi, Khalloufi, Mohammed, Boubaya, Marouane, Le Roy, Christine, Varin-Blank, Nadine, Delmer, Alain, Levy, Vincent, and Ajchenbaum-Cymbalista, Florence more...
- Published
- 2015
- Full Text
- View/download PDF
35. Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization
- Author
-
Reiner Siebert, Anne Quinquenel, Romain Guieze, Catherine Thieblemont, Frederic Davi, Caroline Dartigeas, Sébastien Hergalant, Mathilde Hunault, Florence Cymbalista, Christof Schneider, Marie-Christine Béné, Cécile Tomowiak, Thomas Remen, Kamel Laribi, Damien Roos-Weil, Julien Broséus, Gregory Lazarian, Francis Guillemin, Odile Blanchet, Florian Bouclet, Elise Chapiro, Eugen Tausch, Stephan Stilgenbauer, Sandra Lomazzi, Florence Nguyen-Khac, Pierre Feugier, Charline Moulin, Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département Méthodologie Promotion Investigation [CHRU Nancy] (MPI), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Universitaire de Reims (CHU Reims), Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Universität Ulm - Ulm University [Ulm, Allemagne], Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord, Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre de Ressources Biologiques - [Nancy] (CRB Nancy), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Centre Hospitalier Le Mans (CH Le Mans), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hergalant, Sébastien, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes) more...
- Subjects
Oncology ,[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,medicine.medical_specialty ,Richter syndrome ,[SDV.MHEP.AHA] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,MEDLINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Internal medicine ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,[SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Medicine ,Humans ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM] ,0303 health sciences ,business.industry ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Hematology ,medicine.disease ,Prognosis ,Survival Analysis ,3. Good health ,[STAT] Statistics [stat] ,[STAT]Statistics [stat] ,Leukemia ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Mutation ,Disease Progression ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,France ,Lymphoma, Large B-Cell, Diffuse ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] ,business - Abstract
International audience
- Published
- 2021
- Full Text
- View/download PDF
36. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )
- Author
-
Lazarian, Grégory, primary, Munger, Michaël, additional, Quinquenel, Anne, additional, Dilhuydy, Marie‐Sarah, additional, Veronese, Lauren, additional, Luque Paz, Damien, additional, Guièze, Romain, additional, Ledoux‐Pilon, Albane, additional, Paillassa, Jérôme, additional, Merabet, Fatiha, additional, Vial, Jean‐Philippe, additional, Bidet, Audrey, additional, Waultier Rascalou, Agathe, additional, Broseus, Julien, additional, Roos‐Weil, Damien, additional, Lavaud, Anne, additional, Molina, Lysiane, additional, Laribi, Kamel, additional, Hivert, Bénédicte, additional, Friedrich, Chloé, additional, Carpentier, Benjamin, additional, Ysebaert, Loïc, additional, Van Den Neste, Eric, additional, Willems, Lise, additional, Corby, Anne, additional, Poulain, Stéphanie, additional, Eclache, Virginie, additional, Maubec, Eve, additional, Martin, Antoine, additional, Feugier, Pierre, additional, Delmer, Alain, additional, Baran‐Marszak, Fanny, additional, Leprêtre, Stéphane, additional, and Cymbalista, Florence, additional more...
- Published
- 2021
- Full Text
- View/download PDF
37. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)
- Author
-
Anne Lavaud, Audrey Bidet, Damien Roos-Weil, Benjamin Carpentier, Stéphane Leprêtre, Antoine Martin, Lauren Veronese, Alain Delmer, Loic Ysebaert, Bénédicte Hivert, Julien Broséus, Anne Corby, Eric Van Den Neste, Stéphanie Poulain, Agathe Waultier Rascalou, Kamel Laribi, Damien Luque Paz, Romain Guieze, Lise Willems, Jérôme Paillassa, Fatiha Merabet, Jean-Philippe Vial, Fanny Baran-Marszak, Pierre Feugier, Albane Ledoux-Pilon, Anne Quinquenel, Michaël Munger, Florence Cymbalista, Virginie Eclache, Eve Maubec, Chloé Friedrich, Marie-Sarah Dilhuydy, Lysiane Molina, Grégory Lazarian, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord, Hôpital de l'Enfant-Jésus [CHU Québec] (HEJ), CHU de Québec–Université Laval, Université Laval [Québec] (ULaval)-Université Laval [Québec] (ULaval), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), CRHU Nancy, Unité clinique de pathologie neuromusculaire [CHU Pitié-Salpêtrière], Institut de Myologie, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Le Mans (CH Le Mans), Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cliniques Universitaires Saint-Luc [Bruxelles], Centre Hospitalier de la Rochelle (CH la Rochelle), Centre de Biologie Pathologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Avicenne [AP-HP], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), FAYE, Fatimata, Signalisation, Microenvironnement et Hémopathies Lymphoïdes B (SIMHEL), Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM) more...
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Chronic lymphocytic leukemia ,Internal medicine ,medicine ,Humans ,ComputingMilieux_MISCELLANEOUS ,Aged ,Skin ,Aged, 80 and over ,B-Lymphocytes ,business.industry ,Leukemia cutis ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Middle Aged ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,3. Good health ,Leukemia ,Treatment Outcome ,Mutation ,Female ,France ,medicine.symptom ,business - Abstract
TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary cutaneous malignancies, as patients are at high risk of developing basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Specific cutaneous infiltration by neoplastic B lymphocytes with clinically identifiable skin lesions, also called leukemia cutis (LC), is more uncommon and has seldom been reported in chronic lymphocytic leukemia. [...] more...
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
- Author
-
UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, Cymbalista, Florence, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, and Cymbalista, Florence more...
- Abstract
TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary cutaneous malignancies, as patients are at high risk of developing basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Specific cutaneous infiltration by neoplastic B lymphocytes with clinically identifiable skin lesions, also called leukemia cutis (LC), is more uncommon and has seldom been reported in chronic lymphocytic leukemia. [...] more...
- Published
- 2021
39. Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
- Author
-
Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Magali, Tavernier, Morisset, Stéphane, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Leblond, Veronique, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen Khac, Florence, Rouillé, Valerie, and Delmer, Alain Jacques more...
- Published
- 2023
- Full Text
- View/download PDF
40. Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization
- Author
-
Moulin, Charline, Guillemin, Francis, Remen, Thomas, Bouclet, Florian, Augé, Hélène, Quinquenel, Anne, Dartigeas, Caroline, Morizot, Romain, Lomazzi, Sandra, Busby, Hélène, Hergalant, Sebastien, Tausch, Eugen, Tomowiak, Cécile, Leblond, Veronique, Thieblemont, Catherine, Cymbalista, Florence, Laribi, Kamel, Bene, Marie C, Stilgenbauer, Stephan, Guieze, Romain, Feugier, Pierre, and Broséus, Julien more...
- Published
- 2020
- Full Text
- View/download PDF
41. Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization
- Author
-
Moulin, Charline, primary, Guillemin, Francis, additional, Remen, Thomas, additional, Bouclet, Florian, additional, Hergalant, Sébastien, additional, Quinquenel, Anne, additional, Dartigeas, Caroline, additional, Tausch, Eugen, additional, Lazarian, Grégory, additional, Blanchet, Odile, additional, Lomazzi, Sandra, additional, Chapiro, Elise, additional, Schneider, Christof, additional, Nguyen‐Khac, Florence, additional, Davi, Frédéric, additional, Hunault, Mathilde, additional, Tomowiak, Cécile, additional, Roos‐Weil, Damien, additional, Siebert, Reiner, additional, Thieblemont, Catherine, additional, Cymbalista, Florence, additional, Laribi, Kamel, additional, Béné, Marie‐Christine, additional, Stilgenbauer, Stephan, additional, Guièze, Romain, additional, Feugier, Pierre, additional, and Broséus, Julien, additional more...
- Published
- 2021
- Full Text
- View/download PDF
42. Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group
- Author
-
Christine Carapito, Florian Bouclet, Veronique Leblond, Anne Quinquenel, Cécile Tomowiak, Catherine Thieblemont, Romain Piucco, Pierre Feugier, Aurore Perrot, Marie C. Béné, Caroline Dartigeas, Hélène Busby, Sébastien Hergalant, Florence Cymbalista, Romain Guieze, Luc Mathieu Fornecker, Stephan Stilgenbauer, Sandra Lomazzi, Romain Morizot, Hélène Augé, Julien Broséus, Eugen Tausch, Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Service d'hématologie [Reims], Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims)-Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Universitätsklinikum Ulm - University Hospital of Ulm, Service de Pathologie [CHRU Nancy], Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire de Spectrométrie de Masse BioOrganique [Strasbourg] (LSMBO), Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires (DSA-IPHC), Institut Pluridisciplinaire Hubert Curien (IPHC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut Pluridisciplinaire Hubert Curien (IPHC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie [IUCT Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Institut Pluridisciplinaire Hubert Curien (IPHC), and Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS) more...
- Subjects
Richter syndrome ,Scale (ratio) ,Immunology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Computational biology ,[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC] ,Biology ,Proteomics ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,medicine ,health care economics and organizations ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,[SDV.BBM.MN]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular Networks [q-bio.MN] ,Cell Biology ,Hematology ,medicine.disease ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,3. Good health ,[MATH.MATH-PR]Mathematics [math]/Probability [math.PR] ,030220 oncology & carcinogenesis ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
Richter syndrome (RS) occurs during the disease course of 2 to 10% of Chronic Lymphocytic Leukemia (CLL). Diffuse Large B-Cell Lymphoma (DLBCL) subtype accounts for 90-95% of RS cases. While presenting with the same morphology as de novo DLBCLs, DLBCL subtype of RS is associated with a very poor outcome. Proteins are the primary cellular biological effectors. Proteome composition is highly dependent on regulatory mechanisms located both upstream and downstream translation (transcriptional regulation, post-translational modifications, protein metabolism). Thus, the analysis of the genome and the transcriptome only allows a putative extrapolation of the expressed proteome. Proteomic studies have been performed in the context of de novo DLBCLs (Fornecker et al. Sci Rep. 2019), unravelling a set of proteins associated with refractoriness. In CLL, it showed different profiles according to IGHV mutational status after B-Cell Receptor activation (Perrot et al. Blood 2011). No proteomic study of RS has been carried out to date. RS sample selection was performed across 7 French institutions affiliated to the FILO (French Innovative Leukemia Organization). A total of 49 fresh frozen biopsies were collected, including 28 de novo DLBCLs and 21 RS, mostly treated with first line R-CHOP. All biopsies were centrally reviewed. RS samples were characterized, with data on CLL-RS clonal relationship and mutational status for a 13-gene panel representing the most frequently mutated genes in CLL. Only DLBCL subtype RS samples with at least 50% tumor purity (range 50-95%) and a minimum 10 mg weight were selected. Peptide measurements were performed using liquid chromatography coupled with tandem mass spectrometry, according to published methods (Muller et al. Sci Rep. 2018). Stringent quality controls were applied to ensure sample integrity, abundance accuracy and overall reproducibility. Proteome reconstruction at peptide and at protein level was achieved with a specifically devised pipeline involving conditional filtering, full normalization, categorization and imputation of missing values. These tools made use of the R/Bioconductor DEP package (Zhang et al. Nat Protoc. 2018). Supervised (Bayesian linear models) and unsupervised (hierarchical clustering, K-means, PCA) analyses were further applied to identify differential protein signatures. These were functionally annotated with ReactomePA (Yu et al. Mol Biosyst. 2016) for pathways and STRING (Szklarczyk et al. Nucleic Acids Res. 2019) for association networks. Extended proteomics analysis identified 1,772 proteins, among which 191 were differentially expressed (False Discovery Rate/FDR < 0.05) in RS samples compared to de novo DLBCLs, with 82 increased and 109 decreased proteins. Hierarchical clustering revealed a highly correlated expression profile of these top candidates and clearly separated the 21 RS and the 28 de novo DLBCL samples (Figure 1). Sample distribution was independent from chemosensitivity/resistance, for DLBCL samples, and also unrelated to GCB/Non-GCB phenotype according to Hans algorithm, Epstein-Barr virus positivity or tumor purity. Functional interactome is an in silico protein-protein interaction network built on published data from the literature and available in public databases. The functional interactome computed from the 82 proteins overexpressed in RS showed a strongly enriched association network (protein-protein interactions; p-value < 1e-16), with an over-representation in BCR pathway, VEGF signaling, JAK-STAT pathway and Interleukin-12, Rho GTPase, and actin coiling (FDR < 0.05; Figure 1). Proteins underexpressed in RS (109) also displayed highly associated interactions (p-value < 1e-16) with a main node including proteins involved in cell death regulation, extracellular matrix organization, regulation of Insulin Growth Factor, and signaling by receptor tyrosine kinase (FDR < 0.05; Figure 1). Here we performed proteomics on a 49-sample cohort of 28 de novo DLBCLs and 21 RS, which revealed a specific and differential signature in RS. This includes increased expression of targets within the druggable signaling pathways BCR and JAK-STAT. Furthermore the decrease in proteins involved in cell death regulation and extracellular matrix organization suggests resistance mechanisms to apoptosis and immune system in RS. Disclosures Dartigeas: Janssen: Honoraria; Roche: Honoraria; Gilead: Other: non-financial support. Tausch:AbbVie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Research Funding. Leblond:AstraZeneca: Consultancy, Honoraria; Lilly: Consultancy; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Honoraria; Gilead: Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: Travel/accommodations/expenses, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Other: Travel/accommodations/expenses, Research Funding, Speakers Bureau. Thieblemont:Hospira: Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Bristol-Myers Squibb: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Cellectis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Incyte: Honoraria; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Bayer: Honoraria. Stilgenbauer:Mundipharma: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Honoraria, Other, Research Funding; Pharmacyclics: Consultancy, Honoraria, Other, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; Genentech: Consultancy, Honoraria, Other: travel support, Research Funding; Genzyme: Consultancy, Honoraria, Other: travel support, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Other: travel support, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Other: travel support, Research Funding; Amgen: Consultancy, Honoraria, Other: travel support, Research Funding; AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding. Guieze:abbvie: Honoraria, Other: advisory board, travel funds; janssen cilag: Honoraria, Other: advisory board, travel funds; roche: Other: travle funds; gilead: Honoraria, Other: travel funds; astrazanecka: Honoraria, Other: advisory board. Perrot:Amgen, BMS/Celgene, Janssen, Sanofi, Takeda: Consultancy, Honoraria, Research Funding. Feugier:astrazeneca: Consultancy, Honoraria, Research Funding; abbvie: Consultancy, Honoraria, Research Funding; roche: Consultancy, Honoraria, Research Funding; gilead: Consultancy, Honoraria, Research Funding; janssen: Consultancy, Honoraria, Research Funding. Broséus:AstraZeneca: Consultancy, Honoraria; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Gilead: Honoraria. more...
- Published
- 2020
- Full Text
- View/download PDF
43. Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization
- Author
-
Romain Guieze, Thomas Remen, Julien Broséus, Catherine Thieblemont, Stephan Stilgenbauer, Sandra Lomazzi, Eugen Tausch, Florian Bouclet, Hélène Busby, Kamel Laribi, Veronique Leblond, Marie C. Béné, Florence Cymbalista, Caroline Dartigeas, Sébastien Hergalant, Cécile Tomowiak, Romain Morizot, Hélène Augé, Charline Moulin, Francis Guillemin, Anne Quinquenel, Pierre Feugier, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Service d'Hématologie [CHRU Nancy], Service d'hématologie [Reims], Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims)-Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Pathologie [CHRU Nancy], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Universität Ulm - Ulm University [Ulm, Allemagne], Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Centre Hospitalier Le Mans (CH Le Mans), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes) more...
- Subjects
Oncology ,medicine.medical_specialty ,Richter syndrome ,Immunology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,0303 health sciences ,[INFO.INFO-DB]Computer Science [cs]/Databases [cs.DB] ,business.industry ,Retrospective cohort study ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Cell Biology ,Hematology ,medicine.disease ,3. Good health ,[STAT]Statistics [stat] ,Leukemia ,business ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
Richter Syndrome (RS) corresponds to the transformation of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) into an aggressive lymphoma, in most cases a Diffuse Large B-Cell Lymphoma (DLBCL). RS outcome is variable and still poorly understood. The aim of our study was to analyze the clinical, biological and molecular features liable to predict survival in a retrospective series of newly diagnosed RS from the French Innovative Leukemia Organization (FILO). From 10 French centers, 103 biopsy-confirmed DLBCL subtype RS, diagnosed from 2001 to 2019, were identified. Fresh-frozen biopsies (FB) were available in 58 cases. All biopsies were centrally reviewed. Clinical and biological characteristics at CLL and RS diagnoses including cytogenetics, clonal relationship with the pre-existing CLL, Epstein-Barr virus (EBV) status, cell of origin (COO) according to the Hans algorithm, RS prognostic scores (Tsimberidou et al. J Clin Oncol. 2006, Rossi et al. Blood 2011) as well as treatment and outcomes were collected. Targeted next generation sequencing was used on RS FB for the following gene set: TP53, ATM, SF3B1, NOTCH1, BIRC3, FBXW7, RPS15, EGR2, MYD88, XPO1, POT1, BRAF, and NFKBIE. Overall Survival (OS) was defined as time from RS diagnosis until the date of death or end of follow-up and analyzed using Kaplan-Meier method. Multivariable analysis was performed using Cox regression model for variables with a p-value Clinical and biological characteristics and outcomes were broadly similar between the full 103-patient cohort and the subset of 58 patients with available gene mutation data. The latter only was considered for the subsequent analyses. The median age at CLL/SLL diagnosis was 60 (range 34-81) and 39 patients (67.2%) were male. Prior to RS, 24 (41.38%) received more than 1 line of treatment for CLL. The median time to transformation was 5 years (range 0-22). The median OS from RS diagnosis was 8 months (Figure 1a). The median age at RS diagnosis was 65.5 years (range 42-87). ECOG Performance Status (PS) was >1 in 29/53 patients (54.8%) and 32/56 (57.1%) had a Bulky disease. Elevated Lactate DeHydrogenase (LDH) levels (≥ 1.5N) were found in 38/49 patients (77.6%). Unmutated IGHV was observed in 45/58 (77.6%) RS samples. CLL and RS were clonally related for 29/33 (87.9%) RS with available IGHV sequence at CLL diagnosis. TP53 disruption was detected in 34/56 (60.7%) RS cases including TP53 mutations in 23/58 (39.7%). According to Tsimberidou et al., 10/46 (21.7%) RS were in the low-risk group, 10 in the low-intermediate risk group, 11 (23.9%) in the high-intermediate risk group and the other 15 in the high-risk group. According to the Rossi score, only 4/51 RS (7.8%) were low risk, and 19 (37.3%) and 28 (54.9%) intermediate and high-risk, respectively. The most frequent treatment for RS was R-CHOP-like regimen [38/56 (67.9%)], 5 and 2 patients received autologous or allogeneic stem cell transplantation respectively. Most patients, 40/56 (71.4%) failed to reach complete remission after the first line. By bivariate analysis (Figure 1b-e), ECOG PS, platelet count and TP53 disruption worsened OS (p1, platelet count RS outcome is poor. Here, we focused specifically on Richter cells on diagnostic biopsies for genetic analyses. Unmutated IGHV status was identified as prognostic factor for RS, in addition to the previously described: ECOG PS, platelet count and TP53 disruption. More molecular studies are necessary to increase knowledge about RS and improve the survival of patients with DLBCL-type RS. Disclosures Dartigeas: Janssen: Honoraria; Roche: Honoraria; Gilead: Other: non-financial support. Tausch:Roche: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Research Funding. Leblond:Roche: Consultancy, Honoraria, Other: Travel/accommodations/expenses, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: Travel/accommodations/expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Amgen: Honoraria; AstraZeneca: Consultancy, Honoraria; Lilly: Consultancy. Thieblemont:Incyte: Honoraria; Bristol-Myers Squibb: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Cellectis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Hospira: Research Funding; Bayer: Honoraria. Laribi:abbvie: Honoraria, Research Funding; amgen: Research Funding; novartis: Honoraria, Research Funding; takeda: Research Funding. Stilgenbauer:F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding; Genentech: Consultancy, Honoraria, Other: travel support, Research Funding; Genzyme: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding; Mundipharma: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Honoraria, Other, Research Funding; Pharmacyclics: Consultancy, Honoraria, Other, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Other: travel support, Research Funding; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding; Amgen: Consultancy, Honoraria, Other: travel support, Research Funding; AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding. Guieze:abbvie: Honoraria, Other: advisory board, travel funds; janssen cilag: Honoraria, Other: advisory board, travel funds; roche: Other: travle funds; gilead: Honoraria, Other: travel funds; astrazanecka: Honoraria, Other: advisory board. Feugier:gilead: Consultancy, Honoraria, Research Funding; janssen: Consultancy, Honoraria, Research Funding; roche: Consultancy, Honoraria, Research Funding; abbvie: Consultancy, Honoraria, Research Funding; astrazeneca: Consultancy, Honoraria, Research Funding. Broséus:Novartis: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Gilead: Honoraria. more...
- Published
- 2020
- Full Text
- View/download PDF
44. Autoimmune haemolytic anaemia associated with COVID‐19 infection
- Author
-
Anne Quinquenel, Thorsten Braun, Arsène Mekinian, C Jacquy, Alain Delmer, Gandhi Damaj, Daniel Re, Justine Siavellis, Mathieu Bellal, Fatiha Merabet, Florence Cymbalista, and Gregory Lazarian
- Subjects
Male ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Betacoronavirus ,COVID‐19 ,Pandemic ,Correspondence ,medicine ,Humans ,Child ,Pandemics ,autoimmune hemolytic anemia ,Aged ,B‐cell lymphoproliferative disorder ,biology ,business.industry ,SARS-CoV-2 ,COVID-19 ,Hematology ,Middle Aged ,biology.organism_classification ,medicine.disease ,Virology ,Female ,Anemia, Hemolytic, Autoimmune ,Autoimmune hemolytic anemia ,Coronavirus Infections ,business - Published
- 2020
45. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
- Author
-
Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, and Alain Delmer more...
- Subjects
Oncology ,medicine.medical_specialty ,Venetoclax ,business.industry ,Chronic lymphocytic leukemia ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Ibrutinib ,medicine ,business ,Intermediate risk - Abstract
With the emergence of targeted therapies, defining the best strategy for the treatment of previously untreated CLL patients remains challenging. The aim of this phase 2 study was to compare the efficacy of an association with ibrutinib and venetoclax (IV) to the standard FCR regimen in fit patients with intermediate risk CLL defined by either unmutated IGHV status, 11q deletion or complex karyotype in the absence of TP53 abnormality. Patients were randomized 1:1 between two treatment arms, ie FCR 6 cycles or IV. After a lead-in phase of ibrutinib as a single agent from month (M)1 to M3, the total duration of treatment with IV was based on the response achieved at M9; if bone marrow (BM) MRD was < 0.01% using flow cytometry, the treatment was continued for 6 additional months until M15 and then stopped; if BM MRD at M9 was ≥ 0.01%, the treatment with IV was continued for 18 additional months until M27. The primary endpoint was the percentage of patients with BM MRD < 0.01% at M27 in both arms. We present here the preliminary results on the first evaluation done at M9 including CT-scan, BM biopsy and MRD assessment in PB and BM after the inclusion of all the 120 patients as initially planned. One hundred and twenty patients were enrolled from September 2019 to February 2021. The median age was 59 [34-72] and 61 [34-74] years in the FCR and IV arms, respectively. The characteristics of the patients were well balanced between the 2 arms in terms of gender (male 72% FCR, 74% IV), PS ECOG 0-1 (59% FCR, 68% IV) and Binet stage (A, B and C 15%, 64%, 21% for FCR ; 8.5%, 59% and 32% for IV). No major difference in terms of cytogenetic features was noted, all patients but one had unmutated IGHV. At the time of data cut-off for this interim analysis, the median follow-up for the all cohort was 11 [2.9 - 19.8] months. The frequency of all grades adverse events (AE) observed so far was 53% (grade 3-4, 24%) in the FCR arm and 47% (grade 3-4, 17%) in the IV arm. The rate of infusion-related reactions (IRR) in the FCR arm was 35% on cycle 1-day 1 (14% grade 3-4) ; for the IV arm, 6% of patients experienced tumor lysis syndrome (TLS) (grade 4 for 4 patients). ibrutinib doses were reduced for 7 patients (4 permanently stopped and 3 resumed at a lower dose because of toxicities (digestive, hepatic or haematological)). Venetoclax was permanently discontinued before M9 in 4 patients (digestive toxicities and grade 4 neutropenia). Forty serious adverse events were reported of which 15 in the IV arm (1 sudden death, 1 ischemic stroke, 2 atrial fibrillations, 2 clinical TLS, 1 hepatitis, 1 neutropenia, 4 COVID pneumonitis and one osteoporotic fracture) and 25 in the FCR arm (2 neutropenias, 1 anemia, 1 thrombocytopenia, 1 autoimmune haemolytic anemia, 3 IRR, 4 TLS, 2 COVID pneumonitis, 4 fever episodes of undetermined origin, 1 community-acquired pneumonia, 1 gastrointestinal toxicity, 1 confusion, 2 chest pains, 1 acute myeloid leukemia, 1 myelodysplasic syndrome). The patients with COVID pneumonitis had a favorable evolution with the need for intensive care and convalescent plasma for 3 of them. The first 60 patients included in the study have reached M9 and among them, 6 prematurely discontinued the study, 3 in each arm (active hemolysis, ischemic stroke and sudden death in the IV arm; 2 grade 4 hematologic toxicities and 1 early progression in the FCR arm). In the evaluated patients (n=54), 71% of patients in the FCR arm and 48% of patients in the IV arm achieved bone BM MRD < 0.01%. The complete (CR, CRi) and partial response rates were 54% and 46% in the FCR arm and 76% and 24% in the IV arm respectively. In conclusion, the preliminary results show a lower BM MRD rate in the IV arm compared to the FCR arm at M9, with a toxicity that remains significant and relatively similar between the two arms. However, BM MRD rate should improve after longer exposure to the IV combination and the analysis of the primary endpoint at M27 will be decisive in determining the best therapeutic strategy. Disclosures Quinquenel: Abbvie: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria. Laribi: Le Mans Hospital: Research Funding; Novartis: Other: Personal Fees, Research Funding; Takeda: Other: Personal Fees, Research Funding; BeiGene: Other: Personal Fees; IQONE: Other: Personal Fees; AbbVie: Other: Personal Fees, Research Funding; Astellas Phama, Inc.: Other: Personal Fees; AstraZeneca: Other: Personal Fees; Jansen: Research Funding. Cymbalista: Lilly-LOXO: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; ASTRA ZENECA: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Leblond: AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lilly: Consultancy; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Roche: Honoraria; Amgen: Honoraria; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Dartigeas: Astra-Zeneca: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress. Ferrant: Janssen: Other: Travel, Accommodations, Expenses; AbbVie: Honoraria, Other: Travel, Accommodations, Expenses; AstraZeneca: Honoraria. de Guibert: Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria. Feugier: Astrazeneca: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Amgen: Honoraria; Janssen: Consultancy, Honoraria. Cartron: Roche, Celgene-BMS: Consultancy; Danofi, Gilead, Novartis, Jansen, Roche, Celgene-BMS, Abbvie, Takeda: Honoraria. Ysebaert: Abbvie, AstraZeneca, Janssen, Roche: Other: Advisory Board, Research Funding. more...
- Published
- 2021
- Full Text
- View/download PDF
46. Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group
- Author
-
Stéphane Leprêtre, Emmanuelle Ferrant, Daniel Re, Alexandra Fayault, Romain Guieze, Diane Lara, Philippine Robert, Alain Delmer, Aline Clavert, Fatiha Merabet, Kamel Laribi, Cécile Tomowiak, Fontanet Bijou, Marie-Sarah Dilhuydy, Anne Quinquenel, Marguerite Vignon, Emmanuelle Tchernonog, Charlotte Doublet, Caroline Dartigeas, Anne-Sophie Michallet, and Pierre Feugier more...
- Subjects
medicine.medical_specialty ,chemistry.chemical_compound ,chemistry ,Venetoclax ,business.industry ,Internal medicine ,Immunology ,medicine ,Retrospective cohort study ,Cell Biology ,Hematology ,business ,Biochemistry - Abstract
Median age at diagnosis of chronic lymphocytic leukemia is 72 years. However, only few patients over 80 years of age are included in clinical trials, even in those devoted to unfit patients. In order to evaluate both efficiency and safety of venetoclax in this category of patients, we conducted a multicentric retrospective study and collected data from 77 CLL patients from 19 FILO centers who started venetoclax after 80 years of age. Median age at venetoclax initiation was 86 years old (81-97). 63% of patients had a history of heart disease, 62% had renal failure (moderate 59% and severe 3%) and 29% had a history of severe infections. Despite their comorbidities and a CIRS greater than 6 in 70% of cases, their autonomy was preserved with a median performans status of 1 (0-4). In this comorbid geriatric population, pretherapeutic geriatric assessment was only performed in a single patient. The median number of prior therapies was 2 (0-6) with an exposure to a BCR inhibitor in 56% of cases. 11q and 17p deletion were found in 39% and 30% of cases respectively, 39% of patients had a complex karyotype and 30% harbored a TP53 mutation. However, in this real life population, these prognostic factors were only performed in half of patients. IGHV mutational status was only available in 11 patients, and 83% of them had unmutated IGHV. At the time of venetoclax initiation, the tumor lysis syndrome (TLS) risk was moderate in 57% of cases and high in 8% of cases. Venetoclax was administered as a single agent (42%) or in association with rituximab (58%). In total, half of the patients were hospitalized at each dose ramp-up, and only 3 patients were treated on outpatient basis. 82% of the cohort was able to reach the daily dose of 400mg. Half of the patients were included in a phone call monitoring program with oncology nurses to pre-emptively manage side effects and foster therapy adherence. The safety study reported 14% of TLS, with 2 discontinuations of treatment within the first month: one of which led to dialysis and the other to death. As in the previously published studies, 25% of patients had infectious complications, and grade 3 haematological and digestive toxicities were reported in 42% and 22% of cases, respectively. The reduction of the daily dose of venetoclax was necessary for 33%. Permanent discontinuation of venetoclax occurred in 40% of subjects, including 29% of early withdrawal (within the first 3 months). Main reasons for discontinuation were intolerance (21%), CLL progression (21%), death (21%) and scheduled treatment discontinuation (10%). The overall response rate was 86%, consisting of 49% of complete response (unconfirmed by bone marrow biopsy) and 37% of partial response. With a median follow-up of 21months, estimated progression free survival and overall survival were 29 and 38 months respectively. Prior exposure to a BCR inhibitor had no impact on progression free survival. To conclude, venetoclax has a manageable safety profile in elderly patients with comorbidities and can induce prolonged responses. Finally, if additional follow-up by oncology nurses seems to be more and more implemented, the pre-therapeutic onco-geriatric evaluation remains underexploited in this population. Disclosures Ferrant: AstraZeneca: Honoraria; AbbVie: Honoraria, Other: Travel, Accommodations, Expenses; Janssen: Other: Travel, Accommodations, Expenses. Feugier: Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Amgen: Honoraria; Astrazeneca: Consultancy, Honoraria. Laribi: AstraZeneca: Other: Personal Fees; Le Mans Hospital: Research Funding; AbbVie: Other: Personal Fees, Research Funding; Jansen: Research Funding; Novartis: Other: Personal Fees, Research Funding; IQONE: Other: Personal Fees; Astellas Phama, Inc.: Other: Personal Fees; BeiGene: Other: Personal Fees; Takeda: Other: Personal Fees, Research Funding. Tchernonog: JANSSEN: Consultancy; ABBVIE: Consultancy; ASTRAZENECA: Consultancy. Dartigeas: Astra-Zeneca: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: travel grants/Congress. Quinquenel: Abbvie: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria. more...
- Published
- 2021
- Full Text
- View/download PDF
47. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
- Author
-
Quinquenel, Anne, Fornecker, Luc-Matthieu, Letestu, Rémi, Ysebaert, Loïc, Fleury, Carole, Lazarian, Grégory, Dilhuydy, Marie-Sarah, Nollet, Delphine, Guieze, Romain, Feugier, Pierre, Roos-Weil, Damien, Willems, Lise, Michallet, Anne-Sophie, Delmer, Alain, Hormigos, Katia, Levy, Vincent, Cymbalista, Florence, and Baran-Marszak, Fanny more...
- Published
- 2019
- Full Text
- View/download PDF
48. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome
- Author
-
Augé, Hélène, primary, Notarantonio, Anne-Béatrice, additional, Morizot, Romain, additional, Quinquenel, Anne, additional, Fornecker, Luc-Matthieu, additional, Hergalant, Sébastien, additional, Feugier, Pierre, additional, and Broséus, Julien, additional more...
- Published
- 2020
- Full Text
- View/download PDF
49. Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group
- Author
-
Morizot, Romain, primary, Hergalant, Sebastien, additional, Piucco, Romain, additional, Bouclet, Florian, additional, Quinquenel, Anne, additional, Dartigeas, Caroline, additional, Augé, Hélène, additional, Tausch, Eugen, additional, Lomazzi, Sandra, additional, Busby, Hélène, additional, Tomowiak, Cécile, additional, Leblond, Veronique, additional, Thieblemont, Catherine, additional, Cymbalista, Florence, additional, Bene, Marie C, additional, Stilgenbauer, Stephan, additional, Guieze, Romain, additional, Carapito, Christine, additional, Perrot, Aurore, additional, Fornecker, Luc Mathieu, additional, Feugier, Pierre, additional, and Broséus, Julien, additional more...
- Published
- 2020
- Full Text
- View/download PDF
50. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
- Author
-
Quinquenel, Anne, primary, Aurran-Schleinitz, Thérèse, additional, Clavert, Aline, additional, Cymbalista, Florence, additional, Dartigeas, Caroline, additional, Davi, Frédéric, additional, de Guibert, Sophie, additional, Delmer, Alain, additional, Dilhuydy, Marie-Sarah, additional, Feugier, Pierre, additional, Fornecker, Luc-Matthieu, additional, Ghez, David, additional, Guieze, Romain, additional, Laribi, Kamel, additional, Leblond, Véronique, additional, Leprêtre, Stéphane, additional, Letestu, Rémi, additional, Lévy, Vincent, additional, Nguyen-Khac, Florence, additional, Michallet, Anne-Sophie, additional, Tomowiak, Cécile, additional, Tournilhac, Olivier, additional, Ysebaert, Loïc, additional, and Troussard, Xavier, additional more...
- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.